Remove Ethics Remove Pharma Remove Prescription Remove Safety
article thumbnail

The Dark Side of KOL Relationship

Contrarian Sales Techniques

While building and maintaining relationships with key opinion leaders (KOLs) and thought leaders is an essential part of a pharmaceutical sales representative's job, there have been cases where reps have misused their relationship with KOLs to influence prescriptions. Another example is the case of Purdue Pharma and the opioid crisis.

Ethics 52
article thumbnail

How to Work with Patient Advocates, Influencers, and Ambassadors

PM360

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. Patients want to know other patients are involved in what pharma is doing. Learn how pharma is involving them. They want to hear about those patients’ experiences.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clinical trials and pregnancy: regulators weigh in

Clarivate

How feasible is it to establish a drug’s safety for use in a population that may be unwilling or unable to participate in clinical trials? Margolis Center for Health Policy to convene a February 2021 public meeting about scientific and ethical issues associated with enrolling pregnant individuals in clinical trials for drug development.

article thumbnail

The Future of RWE in Clinical Trial Design and Recruitment

Clarify Health

About 10% of pharma companies at this point have active efforts but we’ve started to see some approvals. And, as you get into more specialty and rare conditions, the need from a cost, ethical, and frankly just a workflow perspective is only going to increase,” Mr. Clapsis added. It’s not just the FDA,” he said.

article thumbnail

The Future of RWE in Clinical Trial Design and Recruitment

Clarify Health

About 10% of pharma companies at this point have active efforts but we’ve started to see some approvals. And, as you get into more specialty and rare conditions, the need from a cost, ethical, and frankly just a workflow perspective is only going to increase,” Mr. Clapsis added. It’s not just the FDA,” he said.

article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. With restricted access and reduced prescription of puberty blockers and hormone therapies, the impact on pharmaceutical companies manufacturing these therapies also remains unclear.

Ethics 144